Published in Cancer Weekly, January 8th, 2002
The investigators reported that Revimid demonstrated significant antitumor activity and was generally well tolerated in patients.
"These encouraging results continue to validate our pipeline of IMiD compounds and based on these data we will substantially expand the clinical development of Revimid," said Sol...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.